Ausun Pharm(SH:603229)2025-10-30 08:15Financial Performance - The company's operating revenue for Q3 2025 was ¥164,089,397.31, a decrease of 17.01% compared to the same period last year[3] - The total profit for the period was ¥38,668,274.94, reflecting a decline of 28.01% year-over-year[3] - The net profit attributable to shareholders was ¥37,685,799.29, down 23.33% from the previous year[3] - The basic earnings per share for the quarter was ¥0.05, a decrease of 16.67% compared to the same period last year[3] - Total operating revenue for the first three quarters of 2025 was CNY 645,961,585.61, a decrease of 6.4% compared to CNY 690,126,439.62 in the same period of 2024[16] - Net profit for the first three quarters of 2025 was CNY 207,031,905.94, down 9.6% from CNY 228,985,673.66 in 2024[17] - The company reported a total profit of CNY 233,345,728.07 for the first three quarters of 2025, compared to CNY 261,279,487.39 in 2024, indicating a decline of 10.7%[17] Cash Flow - The net cash flow from operating activities increased significantly by 127.35% to ¥102,241,945.57 for the quarter[8] - Operating cash inflow for the first three quarters of 2025 reached ¥720,011,893.88, an increase of 17.7% compared to ¥611,796,197.96 in the same period of 2024[20] - Net cash flow from operating activities was ¥147,645,612.37, up 76.1% from ¥83,903,512.00 year-over-year[20] - Investment activities generated a net cash outflow of ¥47,837,784.40, an improvement from a net outflow of ¥85,649,460.36 in the previous year[21] - Cash inflow from financing activities totaled ¥307,896,522.55, compared to ¥170,100,000.00 in the same period last year, marking an increase of 81.1%[21] - The ending balance of cash and cash equivalents was ¥1,080,724,603.12, compared to ¥993,570,174.44 at the end of the same period last year, reflecting a net increase of ¥32,143,383.97[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,060,353,890.21, representing a 2.61% increase from the end of the previous year[4] - Current assets increased to CNY 1,793,706,183.58 from CNY 1,709,169,547.87, reflecting a growth of approximately 4.94%[12] - The total liabilities as of the reporting date were CNY 713,053,258.18, slightly up from CNY 710,498,847.68 in the previous year[14] - Total equity attributable to shareholders increased to CNY 2,347,300,632.03 from CNY 2,271,891,202.71, representing a growth of 3.3%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,998[10] - The largest shareholder, Zheng Zhiguo, holds 50.64% of the company's shares, totaling 420,433,703 shares[10] Research and Development - Research and development expenses increased to CNY 81,618,800.72 in 2025, up from CNY 64,018,512.40 in 2024, reflecting a growth of 27.5%[16] Strategic Initiatives - The company is focusing on market expansion and new product development as part of its strategic initiatives moving forward[19] Accounting and Reporting - The company did not apply new accounting standards for the current reporting period[22] - The financial report was released by Zhejiang Aoxiang Pharmaceutical Co., Ltd. on October 30, 2025[23]